Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences (NASDAQ: SSKN) on Oct 3, 2025 highlighted peer‑reviewed evidence validating its XTRAC® 308 nm Excimer Laser as a safe, effective therapy for localized atopic dermatitis.

The release notes the AMA has expanded excimer laser indications to inflammatory and autoimmune skin diseases, enabling Medicare, Medicaid and private payer reimbursement for atopic dermatitis. The PR cites clinical results: 81% itch reduction (Baltás et al.), randomized trial equivalence/superiority vs. clobetasol with longer durability (Brenninkmeijer et al.), and in refractory hand/foot eczema 69% severity reduction, 70% symptom score reduction, 87% clear/almost clear, and average remission of 11.3 months (Shroff et al.). The company emphasizes targeted, steroid‑sparing treatment benefits and reduced UV exposure versus whole‑body phototherapy.

STRATA Skin Sciences (NASDAQ: SSKN) has announced positive results from a new peer-reviewed study published in Lasers in Medical Science, demonstrating the enhanced efficacy of its XTRAC® 308nm Excimer Laser when combined with tacrolimus ointment for treating plaque-type psoriasis.

The study of 100 patients showed that the combination therapy group achieved superior results compared to topical treatment alone. The combination therapy group's mean PASI score decreased from 18.36 to 3.30, significantly outperforming the control group's reduction from 18.62 to 5.23 (p < 0.01). The treatment demonstrated a strong safety profile with no serious adverse events.

This research validates STRATA's personalized medicine approach, potentially strengthening their case for expanded CMS reimbursement and positioning their XTRAC system as a viable non-biologic treatment option.

STRATA Skin Sciences (NASDAQ: SSKN) has announced significant findings from a 251-patient randomized controlled study combining their 308nm Excimer laser with JAK inhibitors for vitiligo treatment. The study, published in the International Journal of Dermatology, demonstrated superior efficacy with 14.20% higher repigmentation compared to monotherapy.

Key results include 100% significant efficacy rate after 52 weeks of treatment, 96.5% pigmentation stability, and a low 8.8% relapse rate at one-year follow-up. The combination therapy showed excellent safety with no serious adverse events. This research supports STRATA's pursuit of expanded reimbursement for various indications, with the company targeting implementation by early 2026.

STRATA Skin Sciences (NASDAQ:SSKN), a medical technology company focused on dermatologic treatments, has completed its previously announced registered direct offering. The company successfully issued 1,097,547 shares of common stock at $2.204 per share, raising gross proceeds of approximately $2.42 million.

The offering, which closed on September 4, 2025, was conducted through Ladenburg Thalmann & Co. Inc. as the exclusive placement agent. STRATA plans to utilize the net proceeds for working capital and general corporate purposes. The securities were offered under an effective S-3 shelf registration statement.

STRATA Skin Sciences (NASDAQ: SSKN) reports significant success with its Elevate 360 (E360) consulting services platform, which helps partner clinics optimize their XTRAC laser treatment operations. The program focuses on implementing best practices in marketing, reimbursement, and patient retention.

Since early 2025, 99 out of 844 clinics have adopted E360, achieving an average 7% year-over-year growth. A notable case study showed one partner's revenue contribution to STRATA increasing from $10,500 in H1 2024 to $61,800 in H1 2025, while expanding from 2 to 9 clinics after implementing E360.

The program helps clinics optimize patient referrals, insurance reimbursement, scheduling, and follow-up visits, particularly beneficial with recent reimbursement improvements for vitiligo and auto-immune skin conditions.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced a $2.42 million registered direct offering of common stock. The company will sell 1,097,547 shares at $2.204 per share, priced at-market under Nasdaq rules.

The offering, expected to close around September 4, 2025, is being conducted with institutional investors, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. STRATA plans to use the proceeds for working capital and general corporate purposes. The offering is being made through a shelf registration statement previously declared effective by the SEC.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Dr. Dolev Rafaeli will deliver a corporate overview presentation at the event, which takes place September 8-10, 2025 at the Lotte New York Palace Hotel.

The presentation will be available on demand starting September 5, 2025 at 7:00 AM ET for registered conference participants. Investors can request one-on-one meetings through the conference registration portal.

STRATA Skin Sciences (NASDAQ: SSKN) has affirmed its strong patent portfolio position for combination therapies using its XTRAC excimer laser with JAK inhibitors, systemic and biologic drugs. The company holds three key patents that protect the combined use of their technology with various therapeutic agents for treating dermatologic conditions.

The company is working with CMS to implement expanded CPT codes that would cover all inflammatory and autoimmune skin conditions, potentially tripling their addressable market by January 2026. This expansion includes conditions like vitiligo, atopic dermatitis, and alopecia areata, beyond their current psoriasis treatment.

STRATA's patents specifically cover the combination of UVB light therapy with systemic drugs, JAK inhibitors, and biological drugs, positioning the company at the forefront of integrative dermatologic treatment. The company is also engaged in defensive litigation with LaserOptek, expecting significant damages and injunctive relief.

STRATA Skin Sciences (NASDAQ: SSKN) reported Q2 2025 financial results showing decreased revenue and wider losses. Revenue declined 9% to $7.7 million, with global recurring revenue down 4% to $5.1 million and equipment revenue falling 18% to $2.5 million.

The company reported a net loss of $2.5 million ($0.60 per share) compared to a $0.1 million loss ($0.03 per share) in Q2 2024. Gross profit margin decreased to 56%, with cash position at $6.0 million as of June 30, 2025.

Key developments include historic expansion of CPT codes for skin disease treatments, potentially tripling the covered patient population, and strategic device management with 21 removals and 19 new placements of XTRAC devices. The company achieved near operating cashflow breakeven when adjusting for certain expenses.